CVS Health (CVS) is a Great Momentum Stock: Should You Buy?

CVS Health carries a Zacks Momentum Style Score of B and a Zacks Rank of #2 (Buy), supported by strong recent price action and positive estimate revisions. Shares are up 6.29% over the past week, 5.36% over the month, 38.13% over the quarter, and 47.1% over the past year, all ahead of the broader market and industry. The full-year consensus EPS estimate rose from $7.14 to $7.44 over the last 60 days, with 12 upward revisions and none lower.

Analysis

CVS looks less like a pure momentum trade and more like a delayed re-rating on improving forward earnings credibility. The first-order move is that estimate revisions are turning higher while the stock is still trading like a defensive retailer/managed-care hybrid; the second-order effect is potential multiple expansion if the market starts treating CVS as a cash-generative healthcare platform rather than a low-growth pharmacy chain. That said, momentum in this name is likely to be fragile if the bid is driven more by short covering than by durable fundamental ownership.

The more interesting implication is relative-value within healthcare. If CVS continues to outperform the Medical Services group while estimates keep inching up, capital can rotate out of richer-quality defensives that lack revision breadth and into laggards with embedded upside. The recent move also sets up a crowdedness risk: when a large-cap healthcare name becomes a consensus momentum winner, incremental upside often compresses quickly once the next estimate reset fails to materialize.

The key catalyst window is the next 4-8 weeks, when the market will test whether the revisions are broad enough to lift FY25/FY26 confidence or just a single-quarter mechanical adjustment. If volume does not expand alongside price, the rally is vulnerable to mean reversion because momentum funds typically require both trend and participation. The contrarian angle: the market may be underestimating how much of CVS’s upside is already discounting a benign reimbursement and utilization backdrop; any deterioration there would hit both earnings power and sentiment simultaneously.

Key Decisions for Investors

• Go long CVS on shallow pullbacks over the next 1-2 weeks; target a 6-10% additional upside if revisions persist, with a stop if price loses the prior breakout zone on rising volume.
• Pair trade: long CVS / short a weaker healthcare services peer basket over 1-2 months to isolate revision momentum; the trade works if CVS continues to outperform on estimate breadth while the group stays range-bound.
• Buy 6-8 week CVS call spreads to express momentum with defined risk; structure for a 2:1 to 3:1 payoff in case the stock reprices higher on continued analyst upgrades.
• Trim or avoid chasing above the current short-term breakout if 20-day volume fails to accelerate; momentum without participation is vulnerable to a fast 3-5% retracement.
• Use a trailing stop rather than a hard target if holding CVS for 3-6 months; the trade thesis depends on estimate revisions, and the position should be cut if FY25 consensus stops rising.